Heart failure & cardiomyopathies
Association of Liver Fibrosis-4 Index with Adverse Outcomes in Hypertrophic Cardiomyopathy Patients
Main finding · MACEResult — go to the resultAdjusted hazard ratio 1.919 95% CI 1.015–3.630Authors' conclusion
Elevated FIB-4 index, indicative of liver fibrosis, is independently associated with an increased risk of long-term MACE in HCM patients.
Study context
- Population
- Consecutive patients with HCM (34.8% females, 66.49 ± 11.43 years)147 with complete follow-up
- Participants
- 187 patients
- Exposure
- FIB-4 ≥ 2.37 vs FIB-4 < 2.37
- FIB-4 ≥ 2.37n = 47
- FIB-4 < 2.37n = 140reference
- Outcome
- Long-term MACE
- Follow-up
- Median 41 (IQR 16-63) months
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
MACE · median 41 months
Adjusted hazard ratio
1.919
95% CI 1.015–3.630
P = 0.045
By group
FIB-4 ≥ 2.37vs FIB-4 < 2.37
adjusted HR 1.919 (95% CI 1.015–3.630); P = 0.045
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | FIB-4 ≥ 2.37 | FIB-4 < 2.37 | Adjusted HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Cardiac deathUnadjusted P = 0.001 | 20.6% | 2.7% | 9.518 (1.718–52.732) | P = 0.010 | |
| 0.050.21520Adjusted hazard ratio (log scale) |
Correlations of FIB-4 index with echocardiographic measures and NT-proBNP
- Left atrium diameter
- r = 0.229; P = 0.003
- Septal thickness
- r = 0.231; P = 0.002
- Posterior wall thickness
- r = 0.235; P = 0.001
- NT-proBNP
- r = 0.271; P < 0.001
- LVEF
- r = −0.185; P = 0.011
Original publication
Association of Liver Fibrosis-4 Index with Adverse Outcomes in Hypertrophic Cardiomyopathy Patients. ESC Heart Fail. Published 24 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →